ENTRY       hsa05332                    Pathway
NAME        Graft-versus-host disease - Homo sapiens (human)
DESCRIPTION Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.
CLASS       Human Diseases; Immune disease
PATHWAY_MAP hsa05332  Graft-versus-host disease
DISEASE     H00084  Graft-versus-host disease
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        112268355  [KO:K07980]
            115653  KIR3DL3; killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3 [KO:K07980]
            3002  GZMB; granzyme B [KO:K01353] [EC:3.4.21.79]
            3105  HLA-A; major histocompatibility complex, class I, A [KO:K06751]
            3106  HLA-B; major histocompatibility complex, class I, B [KO:K06751]
            3107  HLA-C; major histocompatibility complex, class I, C [KO:K06751]
            3108  HLA-DMA; major histocompatibility complex, class II, DM alpha [KO:K06752]
            3109  HLA-DMB; major histocompatibility complex, class II, DM beta [KO:K06752]
            3111  HLA-DOA; major histocompatibility complex, class II, DO alpha [KO:K06752]
            3112  HLA-DOB; major histocompatibility complex, class II, DO beta [KO:K06752]
            3113  HLA-DPA1; major histocompatibility complex, class II, DP alpha 1 [KO:K06752]
            3115  HLA-DPB1; major histocompatibility complex, class II, DP beta 1 [KO:K06752]
            3117  HLA-DQA1; major histocompatibility complex, class II, DQ alpha 1 [KO:K06752]
            3118  HLA-DQA2; major histocompatibility complex, class II, DQ alpha 2 [KO:K06752]
            3119  HLA-DQB1; major histocompatibility complex, class II, DQ beta 1 [KO:K06752]
            3120  HLA-DQB2; major histocompatibility complex, class II, DQ beta 2 [KO:K06752]
            3122  HLA-DRA; major histocompatibility complex, class II, DR alpha [KO:K06752]
            3123  HLA-DRB1; major histocompatibility complex, class II, DR beta 1 [KO:K06752]
            3125  HLA-DRB3; major histocompatibility complex, class II, DR beta 3 [KO:K06752]
            3126  HLA-DRB4; major histocompatibility complex, class II, DR beta 4 [KO:K06752]
            3127  HLA-DRB5; major histocompatibility complex, class II, DR beta 5 [KO:K06752]
            3133  HLA-E; major histocompatibility complex, class I, E [KO:K06751]
            3134  HLA-F; major histocompatibility complex, class I, F [KO:K06751]
            3135  HLA-G; major histocompatibility complex, class I, G [KO:K06751]
            3458  IFNG; interferon gamma [KO:K04687]
            355  FAS; Fas cell surface death receptor [KO:K04390]
            3552  IL1A; interleukin 1 alpha [KO:K04383]
            3553  IL1B; interleukin 1 beta [KO:K04519]
            3558  IL2; interleukin 2 [KO:K05429]
            356  FASLG; Fas ligand [KO:K04389]
            3569  IL6; interleukin 6 [KO:K05405]
            3802  KIR2DL1; killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 [KO:K07981]
            3803  KIR2DL2; killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 [KO:K07981]
            3804  KIR2DL3; killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 [KO:K07981]
            3811  KIR3DL1; killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 [KO:K07980]
            3812  KIR3DL2; killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2 [KO:K07980]
            3813  KIR3DS1; killer cell immunoglobulin like receptor, three Ig domains and short cytoplasmic tail 1 [KO:K07980]
            3821  KLRC1; killer cell lectin like receptor C1 [KO:K06541]
            3824  KLRD1; killer cell lectin like receptor D1 [KO:K06516]
            5551  PRF1; perforin 1 [KO:K07818]
            57292  KIR2DL5A; killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5A [KO:K24232]
            7124  TNF; tumor necrosis factor [KO:K03156]
            940  CD28; CD28 molecule [KO:K06470]
            941  CD80; CD80 molecule [KO:K05412]
            942  CD86; CD86 molecule [KO:K05413]
COMPOUND    C00338  Lipopolysaccharide
            C00533  Nitric oxide
REFERENCE   PMID:16412784
  AUTHORS   Ferrara JL, Reddy P.
  TITLE     Pathophysiology of graft-versus-host disease.
  JOURNAL   Semin Hematol 43:3-10 (2006)
            DOI:10.1053/j.seminhematol.2005.09.001
REFERENCE   PMID:14735553
  AUTHORS   Reddy P.
  TITLE     Pathophysiology of acute graft-versus-host disease.
  JOURNAL   Hematol Oncol 21:149-61 (2003)
            DOI:10.1002/hon.716
REFERENCE   PMID:17900507
  AUTHORS   Sun Y, Tawara I, Toubai T, Reddy P.
  TITLE     Pathophysiology of acute graft-versus-host disease: recent advances.
  JOURNAL   Transl Res 150:197-214 (2007)
            DOI:10.1016/j.trsl.2007.06.003
REFERENCE   PMID:15882431
  AUTHORS   Jaksch M, Mattsson J.
  TITLE     The pathophysiology of acute graft-versus-host disease.
  JOURNAL   Scand J Immunol 61:398-409 (2005)
            DOI:10.1111/j.1365-3083.2005.01595.x
REFERENCE   PMID:12359826
  AUTHORS   Vogelsang GB, Lee L, Bensen-Kennedy DM.
  TITLE     Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant.
  JOURNAL   Annu Rev Med 54:29-52 (2003)
            DOI:10.1146/annurev.med.54.101601.152339
REFERENCE   PMID:14556773
  AUTHORS   Reddy P, Ferrara JL.
  TITLE     Immunobiology of acute graft-versus-host disease.
  JOURNAL   Blood Rev 17:187-94 (2003)
            DOI:10.1016/S0268-960X(03)00009-2
REFERENCE   PMID:16147539
  AUTHORS   Blazar BR, Murphy WJ.
  TITLE     Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).
  JOURNAL   Philos Trans R Soc Lond B Biol Sci 360:1747-67 (2005)
            DOI:10.1098/rstb.2005.1701
REFERENCE   PMID:15372473
  AUTHORS   Couriel D, Caldera H, Champlin R, Komanduri K.
  TITLE     Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.
  JOURNAL   Cancer 101:1936-46 (2004)
            DOI:10.1002/cncr.20613
REFERENCE   PMID:17784964
  AUTHORS   Jacobsohn DA, Vogelsang GB.
  TITLE     Acute graft versus host disease.
  JOURNAL   Orphanet J Rare Dis 2:35 (2007)
            DOI:10.1186/1750-1172-2-35
REL_PATHWAY hsa04060  Cytokine-cytokine receptor interaction
            hsa04210  Apoptosis
            hsa04514  Cell adhesion molecules
            hsa04612  Antigen processing and presentation
            hsa04620  Toll-like receptor signaling pathway
            hsa04650  Natural killer cell mediated cytotoxicity
            hsa04660  T cell receptor signaling pathway
KO_PATHWAY  ko05332
///
